Longeveron (NASDAQ: LGVN)
LGVN · Nasdaq · United States
Share price · LGVN
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when LGVN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 10 Nov 2026+41.3%
Nothing announced by LGVN that day or the session before.
- 14 Oct 2026-19.5%
- 17 Sep 2026-59.4%
- 11 Sep 2026+10.4%
Nothing announced by LGVN that day or the session before.
- 25 Aug 2026-18.8%
- 17 Aug 2026+10.8%
Nothing announced by LGVN that day or the session before.
- 30 Jul 2026+13.4%
- 24 Jun 2026-7.5%
Nothing announced by LGVN that day or the session before.
- 13 Mar 2026+20.4%
- 10 Mar 2026+68.1%
Share of unusual movement by asset
For each asset, the share of LGVN's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
Laromestrocel (Lomecel-B)events and moves
| 2 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 12% |
| Other company news (earnings, financing, releases naming no asset) | — | 38% |
| Sessions with no dated event | — | 50% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
Laromestrocel(Lomecel-B) | Phase 2 | Mesenchymal stem cell therapyCell therapy | Alzheimer's DiseaseHypoplastic Left Heart Syndrome |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $0.1M | $4.0M | $7.3M | $6.1M-$2.7M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $3.2M | $10M | $6.1M-$5.7M operating cash flow | report ↗ |
| 2026-Q1 | — | $2.3M | $16M | $4.7M-$4.4M operating cash flow | report ↗ |
| 2025-Q3 | — | $3.9M | $9.2M | $7.2M-$5.0M operating cash flow | report ↗ |
| 2025-Q2 | — | $3.0M | $10M | $5.0M-$3.6M operating cash flow | report ↗ |
| 2025-Q1 | — | $2.5M | $14M+ $0 short-term inv. | $5.0M-$4.7M operating cash flow | report ↗ |
| 2024-Q3 | — | $2.2M | $23M+ $0 short-term inv. | $4.4M-$2.8M operating cash flow | report ↗ |
| 2024-Q2 | — | $1.7M | $12M | $3.4M-$4.6M operating cash flow | report ↗ |
| 2024-Q1 | $0.6M | $2.2M | $1.9M+ $0.3M short-term inv. | $4.1M-$3.1M operating cash flow | report ↗ |
| 2023-Q3 | $0.1M | $1.8M | $2.0M+ $2.0M short-term inv. | $5.1M-$4.6M operating cash flow | report ↗ |
| 2023-Q2 | $0.2M | $2.3M | $2.8M+ $5.9M short-term inv. | $5.6M-$4.6M operating cash flow | report ↗ |
| 2023-Q1 | $0.3M | $2.8M | $5.0M+ $0.4M short-term inv. | $4.7M-$5.8M operating cash flow | report ↗ |
| 2022-Q3 | $0.3M | $3.0M | $14M+ $8.7M short-term inv. | $5.2M-$4.2M operating cash flow | report ↗ |
| 2022-Q2 | $0.5M | $1.7M | $20M+ $7.1M short-term inv. | $5.6M-$3.3M operating cash flow | report ↗ |
| 2022-Q1 | $0.4M | $1.4M | $22M+ $8.5M short-term inv. | $3.5M-$4.2M operating cash flow | report ↗ |
| 2021-Q3 | $0.2M | $2.0M | $9.7M+ $9.2M short-term inv. | $4.9M-$2.4M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $12M | $4.7M | $5.7M-$19M operating cash flow | report ↗ |
For fiscal year 2025, Longeveron did not disclose revenue. R&D spend was $12.04M, up 47.9% YoY, while cash and equivalents stood at $4.66M. The company reported a net loss of $22.7M and a quarterly net burn of $22.7M.
Longeveron is advancing laromestrocel across HLHS, Alzheimer’s disease, pediatric DCM, and aging-related frailty. The ELPIS II Phase 2b HLHS trial reached full enrollment on June 24, 2025, with top-line results anticipated in Q3 2026 and an FDA Type C meeting scheduled for late March 2026. In mild Alzheimer’s disease, a positive Type B meeting in March 2025 supported a proposed pivotal Phase 2/3 registrational design. An IND for pediatric DCM became effective in July 2025, with a single pivotal Phase 2 trial planned to begin preparation in 2026, and the company discontinued its Japan frailty trial in April 2024.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $8.1M | $19M+ $0 short-term inv. | $4.0M-$14M operating cash flow | report ↗ |
| 2023-FY | $0.7M | $9.1M | $5.0M+ $0.4M short-term inv. | $5.3M-$19M operating cash flow | report ↗ |
| 2022-FY | $1.2M | $9.4M | $11M+ $9.2M short-term inv. | $4.7M-$14M operating cash flow | report ↗ |
| 2021-FY | $1.3M | $7.1M | $26M+ $9.5M short-term inv. | $4.3M-$9.6M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-01 | Blass Devin · CTO & SVP of CMC | Tax withholding | 2,520 | $2.59 | $7K | Form 4 |
| 2026-10-01 | Lehr Paul T · General Counsel, Secretary | Tax withholding | 2,253 | $2.59 | $6K | Form 4 |
| 2026-10-01 | Agafonova Nataliya · Chief Medical Officer | Tax withholding | 2,913 | $2.59 | $8K | Form 4 |
| 2026-10-01 | Willard Stephen H · Chief Executive Officer | Tax withholding | 1,987 | $2.59 | $5K | Form 4 |
| 2026-10-01 | Jhaveri Nirav S. · Chief Financial Officer | Tax withholding | 742 | $2.59 | $2K | Form 4 |
| 2026-08-19 | Hare Joshua · director, Chief Scientific Officer, 10% owner | Award / grant | 286,000 | — | — | Form 4 |
| 2026-08-19 | Agafonova Nataliya · Chief Medical Officer | Award / grant | 286,000 | — | — | Form 4 |
| 2026-08-19 | Ascheim Deborah · director | Award / grant | 36,000 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 31 reporting institutions held 2.3M shares ($2.2M, 7.3% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 542,032 | $564K |
| 2 | MILLENNIUM MANAGEMENT LLC | 446,725 | $465K |
| 3 | BlackRock, Inc. | 224,198 | $233K |
| 4 | GEODE CAPITAL MANAGEMENT, LLC | 203,618 | $212K |
| 5 | ADAR1 Capital Management, LLC | 200,000 | $208K |
| 6 | JANE STREET GROUP, LLC | 185,656 | $193K |
| 7 | Beacon Pointe Advisors, LLC | 100,000 | $104K |
| 8 | STATE STREET CORP | 45,380 | $47K |
| 9 | VANGUARD FIDUCIARY TRUST CO | 38,715 | $40K |
| 10 | Capital Investment Advisory Services, LLC | 26,525 | $28K |
| 11 | COMMONWEALTH EQUITY SERVICES, LLC | 25,155 | $26K |
| 12 | Hamilton Point Investment Advisors, LLC | 22,446 | $23K |
| 13 | MONETA GROUP INVESTMENT ADVISORS LLC | 21,300 | $22K |
| 14 | NORTHERN TRUST CORP | 19,779 | $21K |
| 15 | UBS Group AG | 14,862 | $15K |